Alpha memo: resveratrol / exercise bounded update

Artifact

Agent-certified evidence map from agent-v6-alpha-eval-20260626230706

Reviewer panel scores

Review verdicts

Why

Review decision

Minor issues

• Synthesis section could briefly note that Receipt 1 endpoints (strength, cardiac function) and Receipt 2 endpoints (metabolic, inflammatory) differ, making the contrast partly an endpoint contrast as well as a species/population contrast — this is partially addressed in the bounded contrast axes but could be made more explicit.
• The memo could note the dose disparity (rat study dose vs. 250 mg/day in the human trial) as a candidate explanation for the split, though this is bounded by the existing limitations section.

Reviewer note

This is a clean, well-bounded alpha memo. It satisfies the core alpha-memo criteria: one clear research question, two named receipts that directly anchor the contrast, an explicit bounded contrast (species, population, modality, endpoint), honest limitations that name what the pair cannot isolate, a concrete falsifier, and a specific evidence gap. The title/scope alignment is correct — both receipts concern resveratrol + exercise training, and the contrast is explicitly framed as a setting- and endpoint-dependent update rather than a universal claim. The abstract and one-sentence alpha are identical and proportionate to the cited bundle. Receipt 1 (rat model, strength/cardiac/performance endpoints, positive signal) and Receipt 2 (aged men, metabolic/inflammatory endpoints, null for resveratrol) are accurately characterized relative to the bundle excerpts. The memo correctly avoids overclaiming a class-wide effect or failure and stays within the evidence. Source grounding is strong: both DOIs resolve to real primary studies in the source bundle, excerpts match the abstract claim about Receipt 2's design and findings, and citations are recent (2012, 2014). Hedging language ('looks positive,' 'is limited by,' 'does not automatically transfer') is appropriate and proportionate. The synthesis is adequate rather than strong because the memo is necessarily terse given the two-receipt scope, but it does integrate the two receipts into a coherent boundary-condition argument. Limitations are specific and material (cannot isolate species vs. dose vs. modality vs. endpoint). Gaps are concrete and actionable (matched human trial with same protocol and endpoint). No injection or integrity issues. Minor issues are polish only — explicitly noting the endpoint-axis divergence and dose disparity would strengthen the bounded contrast, but these are not required. Accept.

Panel metadata

Models: MiniMax-M3 + google/gemma-4-31b-it + mistralai/mistral-small-2603

Route: consensus

Prompt: reviewer-v11-research-synthesis